{
    "title": "The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population",
    "pmid": "39346054",
    "pmcid": "PMC11430164",
    "study_parameters": [],
    "var_drug_ann": [],
    "var_pheno_ann": [],
    "var_fa_ann": [
        {
            "Variant Annotation ID": 1452626580,
            "Variant/Haplotypes": "CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31",
            "Gene": "CYP3A4",
            "Drug(s)": "ticagrelor",
            "PMID": 39346054,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
            "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
            "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
            "Specialty Population": null,
            "Assay type": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Functional terms": "clearance of",
            "Gene/gene product": null,
            "When treated with/exposed to/when assayed with": null,
            "Multiple drugs And/or": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": "*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "39346054",
            "Variant Annotation ID_norm": "1452626580"
        },
        {
            "Variant Annotation ID": 1452626560,
            "Variant/Haplotypes": "CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33",
            "Gene": "CYP3A4",
            "Drug(s)": "ticagrelor",
            "PMID": 39346054,
            "Phenotype Category": "Metabolism/PK",
            "Significance": "yes",
            "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
            "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
            "Alleles": "*11 + *18 + *33",
            "Specialty Population": null,
            "Assay type": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Functional terms": "clearance of",
            "Gene/gene product": null,
            "When treated with/exposed to/when assayed with": null,
            "Multiple drugs And/or": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": "*1",
            "Comparison Metabolizer types": null,
            "PMID_norm": "39346054",
            "Variant Annotation ID_norm": "1452626560"
        }
    ]
}